Abstract

Canine oral tumors are relatively common neoplasms in dogs. For disease monitoring and early diagnosis, salivary biomarkers are appropriate because saliva collection is non-invasive and requires no professional skills. In the era of omics, matrix-assisted laser desorption/ionization with time-of-flight mass spectrometry (MALDI-TOF MS) coupled with liquid chromatography-tandem MS (LC-MS/MS) are suitable to identify potential disease-associated peptides and proteins. The present study aimed to use MALDI-TOF MS and LC-MS/MS to search for particular peptide mass fingerprints (PMFs) and conceivable biomarkers in saliva of dogs with early- and late-stage oral melanoma (EOM and LOM, respectively), oral squamous cell carcinoma (OSCC), benign oral tumors (BN), and periodontitis and healthy controls (CP). Pooled saliva samples in each group were used to be representative of population change. Unique PMFs were obtained and specific peptide fragments were sequenced by LC-MS/MS and BLAST-searched with mammalian protein databases. Seven peptide fragments appeared in the tumor groups (EOM, LOM, OSCC and BN) at 1096, 1208, 1322, 1794, 1864, 2354 and 2483 Da, two peptide fragments appeared in the LOM and OSCC groups at 2450 and 3492 Da, and in the CP controls at 2544 and 3026 Da. Also, protein–chemotherapy drug interaction networks were exhibited. Using western blot analysis, the expression of sentrin-specific protease 7 (SENP7), a peptide fragment at 1096 Da, in OSCC was significantly increased, as was the expression of TLR4, a peptide fragment at 3492 Da, in LOM and OSCC, compared with the CP group. The expression of nuclear factor kappa B (NF-κB), a TLR4 partner, was notably increased in OSCC compared with CP, BN and EOM. The expression was also enhanced in LOM compared with EOM. Expressed protein sequences from western blots were verified by LC-MS/MS. Western blots were then performed with individual samples in each group. The results showed the elevated expression of TLR4 in LOM and OSCC, compared with that in CP and BN, the increased expression of NF-κB in LOM and OSCC, compared with CP and in LOM compared with BN, and the enhanced expression of SENP7 in LOM and OSCC, compared with that in CP and BN. In conclusion, discrete clusters of EOM, LOM, OSCC, BN and CP groups and potential protein candidates associated with the diseases were demonstrated by salivary proteomics. Western blot analysis verified SENP7, TLR4 and NF-κB as potential salivary biomarkers of canine oral tumors.

Highlights

  • Tumors in the oral cavity and gastrointestinal system account for 18% of tumors in dogs and tumors in the oral cavity account for 46% of canine head and neck cancers [1, 2]

  • The cross-validation, calculated by ANOVA, in the CP, benign oral tumors (BN), EOM, LOM, and oral squamous cell carcinoma (OSCC) was 100%, 100%, 96.88%, 100% and 100%, respectively, and the recognition capability, calculated by Quick Classifier (QC)/ Different Average, Supervised Neural Network (SNN), AD, TTA, W/KW and the Genetic Algorithm (GA) test in the CP, BN, EOM, LOM, and OSCC groups was all 100%, indicating that the results were of high reliability

  • Divergent peptide mass fingerprints (PMFs) of CP, EOM, LOM, OSCC and BN groups were observed, and peptide masses at 1000–5000 Da were selected by ClinProTools software and specific peptide sequences were analyzed by LC MS/ MS

Read more

Summary

Introduction

Tumors in the oral cavity and gastrointestinal system account for 18% of tumors in dogs and tumors in the oral cavity account for 46% of canine head and neck cancers [1, 2]. As the oral cavity is not routinely examined by owners or veterinarians, oral cancers are usually detected at a late clinical stage (stages III and IV), based on the World Health Organization (WHO) clinical staging system for tumors of the oral cavity [3]. As defined by their primary sizes and metastatic profile, the tumor, node and metastasis (TNM) stages comprise stage I (a

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call